Stem Cell Modulation II
AssigneeUniversity of Canberra
InventorsSudha RAO, Anjum ZAFAR
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.
Claims26
-74. (canceled)
A method for altering at least one of:
- (i) formation;
- (ii) proliferation;
- (iii) maintenance;
- (iv) epithelial to mesenchymal transition (EMT);
- or (v) mesenchymal to epithelial transition (MET) of a protein kinase C theta (PKC-θ)-overexpressing cell, the method comprising contacting the PKC-θ-overexpressing cell with a formation-, proliferation-, maintenance-;
- EMT- or MET-modulating amount of a PKC-θ inhibitor, wherein the PKC-θ-overexpressing cell is a cancer stem cell (CSC).
A method for treating or preventing a cancer in a subject, wherein the cancer comprises a cancer stem cell (CSC) and a non-CSC tumor cell, the method comprising administering to the subject a protein kinase C theta (PKC-θ) inhibitor in an effective amount to inhibit formation, proliferation, maintenance or epithelial to mesenchymal transition (EMT) of the CSC or to stimulate or induce mesenchymal to epithelial transition (MET) of the CSC.
A method for treating or preventing a cancer in a subject, wherein the cancer comprises a cancer stem cell (CSC) and a non-CSC tumor cell, the method comprising concurrently administering to the subject a protein kinase C theta (PKC-θ) inhibitor in an effective amount to inhibit formation, proliferation, maintenance or epithelial to mesenchymal transition (EMT) of the CSC or to stimulate or induce mesenchymal to epithelial transition (MET) of the CSC, and a cancer therapy or agent that inhibits the proliferation, survival or viability of the non-CSC tumor cell, to thereby treat or prevent the cancer.
Dependencies are inferred from the claim text.